Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed follow...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of translational medicine Vol. 7; no. 5; p. 106
Main Authors:	Bender, Laura, Meyer, Guillaume, Quoix, Elisabeth, Mennecier, Bertrand
Format:	Journal Article
Language:	English
Published:	China 01.03.2019
Subjects:	Anaplastic lymphoma kinase rearrangement (ALK rearrangement) diffuse interstitial pneumonitis ceritinib non-small cell lung cancer (NSCLC)
ISSN:	2305-5839, 2305-5839
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	2305-5839 2305-5839
DOI:	10.21037/atm.2019.01.24